WO2013064672A3 - Einmalig dosierte oxazaphosphorine zur therapie von krankheiten - Google Patents

Einmalig dosierte oxazaphosphorine zur therapie von krankheiten Download PDF

Info

Publication number
WO2013064672A3
WO2013064672A3 PCT/EP2012/071772 EP2012071772W WO2013064672A3 WO 2013064672 A3 WO2013064672 A3 WO 2013064672A3 EP 2012071772 W EP2012071772 W EP 2012071772W WO 2013064672 A3 WO2013064672 A3 WO 2013064672A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxazaphosphorines
time
treating diseases
dosed
ido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/071772
Other languages
English (en)
French (fr)
Other versions
WO2013064672A2 (de
Inventor
Ulf Niemeyer
Jörg POHL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2013064672A2 publication Critical patent/WO2013064672A2/de
Publication of WO2013064672A3 publication Critical patent/WO2013064672A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung betrifft Oxazaphosphorine der Formel (I), worin R1 und R2 2-Chlorethyl oder H ist und R3 2-Sulfonatoethylthio- oder H ist, zur Therapie von Krankheiten, die durch das Tolerogen lndolamin-2,3-dioxygenase (IDO) verursacht oder aufrechterhalten werden, wobei die Oxazaphosphorine der Formel (I) einmalig in einer Dosis von höchstens 0,3 mmol/m2 verabreicht werden und so dem Tolerogen IDO entgegenwirken. Die Erfindung betrifft außerdem die Verwendung dieser Oxazaphosphorine zur Herstellung eines Medikamentes zur Verwendung in der Behandlung von Krankheiten, die durch die Aktivierung der Expression von lndolamin-2,3-dioxygenase (IDO) verursacht oder aufrechterhalten werden, wobei die Oxazaphosphorine der Formel (I) einmalig in einer Dosis von höchstens 0,3 mmol/m2 verabreicht werden.
PCT/EP2012/071772 2011-11-03 2012-11-02 Einmalig dosierte oxazaphosphorine zur therapie von krankheiten Ceased WO2013064672A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011085695.1 2011-11-03
DE102011085695A DE102011085695A1 (de) 2011-11-03 2011-11-03 Einmalig dosierte Oxazaphosphorine zur Therapie von Krankheiten

Publications (2)

Publication Number Publication Date
WO2013064672A2 WO2013064672A2 (de) 2013-05-10
WO2013064672A3 true WO2013064672A3 (de) 2013-07-04

Family

ID=47143899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/071772 Ceased WO2013064672A2 (de) 2011-11-03 2012-11-02 Einmalig dosierte oxazaphosphorine zur therapie von krankheiten

Country Status (2)

Country Link
DE (1) DE102011085695A1 (de)
WO (1) WO2013064672A2 (de)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052598A1 (en) * 1997-05-21 1998-11-26 Genentech, Inc. Novel administration of thrombopoietin
WO1999003976A2 (en) * 1997-07-21 1999-01-28 Cerus Corporation Method of treating leukocytes, leukocyte compositions and methods of use thereof
WO2003103389A2 (en) * 2002-06-10 2003-12-18 Avax Technologies Inc. Cryopreservation of haptenized tumor cells
US20070123518A1 (en) * 2003-10-01 2007-05-31 Epshtein Oleg I Product designed to protentiate the therapeutic effects and to enhance the action of medicinal preparations
US20080131495A1 (en) * 2004-04-01 2008-06-05 Biomira, Inc. Mucinous Glycoprotein (Muc-1) Vaccine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451840B1 (en) 1997-12-05 2002-09-17 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by tryptophan
DE102004050111A1 (de) 2004-10-13 2006-04-27 Pohl, Jörg, Dr. Modulation der Immunregulation
DE102005008797A1 (de) 2005-02-25 2006-09-07 Baxter International Inc., Deerfield Trofosfamid-haltige Filmtabletten und Verfahren zu deren Herstellung

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052598A1 (en) * 1997-05-21 1998-11-26 Genentech, Inc. Novel administration of thrombopoietin
WO1999003976A2 (en) * 1997-07-21 1999-01-28 Cerus Corporation Method of treating leukocytes, leukocyte compositions and methods of use thereof
WO2003103389A2 (en) * 2002-06-10 2003-12-18 Avax Technologies Inc. Cryopreservation of haptenized tumor cells
US20070123518A1 (en) * 2003-10-01 2007-05-31 Epshtein Oleg I Product designed to protentiate the therapeutic effects and to enhance the action of medicinal preparations
US20080131495A1 (en) * 2004-04-01 2008-06-05 Biomira, Inc. Mucinous Glycoprotein (Muc-1) Vaccine

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 12 May 1997 (1997-05-12), DRAGSTED N O ET AL: "[Survival in ovarian cancer treated in a gynecological department of a central hospital].", XP002690616, Database accession no. NLM9190729 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 2006, SWIATONIOWSKI GRZEGORZ ET AL: "[Surprisingly positive effect of palliative CAP chemotherapy of bone-disseminated, undifferentiated carcinoma of unknown primary origin in patient with low performance status according to WHO].", XP002690615, Database accession no. NLM16969902 *
HOON D S B ET AL: "SUPPRESSOR CELL ACTIVITY IN A RANDOMIZED TRIAL OF PATIENTS RECEIVING ACTIVE SPECIFIC IMMUNOTHERAPY WITH MELANOMA CELL VACCINE AND LOW DOSAGES OF CYCLOPHOSPHAMIDE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 50, no. 17, 1 September 1990 (1990-09-01), pages 5358 - 5364, XP001179425, ISSN: 0008-5472 *
N J DAWSON: "THE SURFACE-AREA/BODY-WEIGHT RELATIONSHIP IN MICE", AUST. J. BIOL. SCI., 1967, 20, 1 January 1967 (1967-01-01), pages 687 - 690, XP055049943, Retrieved from the Internet <URL:http://www.publish.csiro.au/?act=view_file&file_id=BI9670687.pdf> [retrieved on 20130116] *
PRZEGLAD LEKARSKI 2006, vol. 63, no. 3, 2006, pages 166 - 168, ISSN: 0033-2240 *
R.E. ELMSLIE ET AL: "Metronomic Therapy with Cyclophosphamide and Piroxicam Effectively Delays Tumor Recurrence in Dogs with Incompletely Resected Soft Tissue Sarcomas", JOURNAL OF VETERINARY INTERNAL MEDICINE, vol. 22, no. 6, 1 November 2008 (2008-11-01), pages 1373 - 1379, XP055050184, ISSN: 0891-6640, DOI: 10.1111/j.1939-1676.2008.0179.x *
TAKASHI FUKUTOMI ET AL: "Adjuvant Six Cycles of High-Dose Adriamycin, Cyclophosphamide, Methotrexate, 5-Fluorouracil (ACMF) vs. 12 Cycles of low-Dose ACMF With Tamoxifen for Premenopausal, Node-Positive Breast Cancer Patients: Results of a Prospective Randomized Study", JOURNAL OF SURGICAL ONCOLOGY 60:242-246 (1995), 1 January 1995 (1995-01-01), pages 242 - 246, XP055049898, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/store/10.1002/jso.2930600406/asset/2930600406_ftp.pdf?v=1&t=hc0grvl2&s=bc50ad3b38a052c7361effd6685bcc87aff19fd6> [retrieved on 20130116] *
UGESKRIFT FOR LAEGER 12 MAY 1997, vol. 159, no. 20, 12 May 1997 (1997-05-12), pages 3003 - 3009, ISSN: 0041-5782 *

Also Published As

Publication number Publication date
WO2013064672A2 (de) 2013-05-10
DE102011085695A1 (de) 2013-05-08

Similar Documents

Publication Publication Date Title
NZ703989A (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MA33939B1 (fr) 5-alcynyl-pyrimidines
JO3091B1 (ar) مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها
EA201201648A1 (ru) Стимуляторы sgc
MX336381B (es) Boronatos como inhibidores de arginasa.
MX2009011473A (es) Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
PH12016501204A1 (en) Syk inhibitors
MX2015008187A (es) Inhibidores de alk deuterados.
MY163202A (en) Indolizine derivatives, proces for the preparation thereof and therapeutic use thereof
MY184306A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
UA115320C2 (uk) Інгібітори кінази
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX2015010354A (es) Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
MD20150048A2 (ro) Derivaţi ai pirolotriazinonei în calitate de inhibitori ai PI3K
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer&#39;s disease
MX2015004362A (es) Derivados de ketamina.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
PH12015502429A1 (en) Dicarboxylic acid compound
MY178390A (en) Inhibitors of iap

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12783204

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12783204

Country of ref document: EP

Kind code of ref document: A2